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NEWS STORY ON TAMIFLU STUDY
Principal author of PRIDE study responds to news
story in The BMJ claiming that the study was based on
“flawed” analysis
Jonathan S Nguyen-Van-Tam clinical professor of health protection, and senior author, PRIDE
Consortium
University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham NG5 1PB, UK
On 19March 2014, researchers from the PRIDE (Post-pandemic
Review of anti-Influenza Drug Effectiveness) Consortium
published the first outputs from a project investigating the
effectiveness of neuraminidase inhibitors against outcomes of
public health importance during the 2009 flu pandemic in the
Lancet Respiratory Medicine.1 2 The headline results suggested
that neuraminidase inhibitors were associated with statistically
significant reductions in mortality: overall adjusted odds ratio
0.81 (95% CI 0.70 to 0.93; P=0.0024) versus no treatment and
0.50 (0.37 to 0.67; P<0.0001) if treatment was started within
two days of symptom onset.
Within 48 hours, The BMJ published an article written by a staff
journalist, which claimed that the new study “was based on
flawed analysis.”3 Zosia Kmietowicz had contactedMark Jones,
University of Queensland, who is working with the Cochrane
Collaboration on another project related to neuraminidase
inhibitors. In turn, Jones had provided a detailed statistical
critique of the PRIDE study, which formed the centrepiece of
Kmietowicz’s article. The PRIDE Consortium was not
forewarned about the article and, more importantly, not offered
any a priori right of reply, as would normally be the case during
post-publication correspondence. Faced with such a one sided
critique of its work, the PRIDE Consortium had no option but
to post its initial rebuttal in The BMJ.4 There has since been a
further critique from Jones and a further statistical rebuttal from
the PRIDE Consortium.5 6
Thus, the correspondence and debate relating to a major
publication in a Lancet Group paper has been played out in the
pages of The BMJ, fronted by an entirely one sided article from
a staff journalist on The BMJ. The major question here seems
to be the propriety of The BMJ and Dr Jones in going beyond
the reasonable response to a press release, by asking potential
opponents for a detailed statistical critique without offering the
authors of the study any right to reply alongside. A more
conventional and considerably more ethical approach would
have been to submit correspondence post-publication to the
Lancet RespiratoryMedicine, which could then have considered
the response in the normal way, including offering the PRIDE
Consortium a realistic period of time to consider the critique
and write a rejoinder.
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